101
|
Tamura T, Sakai D, Sugimoto N, Tokunaga S, Tsuji A, Ishida H, Otsu S, Moriwaki T, Satake H, Uchino K, Matsumoto S, Baba E, Sato M, Taniguchi H, Kishimoto J, Boku N, Hyodo I, Muro K. Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
102
|
Sato M, Veir JK, Legare M, Lappin MR. A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs. J Vet Intern Med 2017; 31:1502-1507. [PMID: 28833582 PMCID: PMC5598884 DOI: 10.1111/jvim.14810] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 04/19/2017] [Accepted: 07/19/2017] [Indexed: 12/18/2022] Open
Abstract
Background Little clinical information is available concerning the use of leflunomide in dogs with immune‐mediated diseases. Objectives To report the safety and efficacy of leflunomide for the treatment of naturally occurring immune‐mediated diseases in dogs. Animals Ninety‐two dogs treated with leflunomide for management of suspected immune‐mediated diseases. Methods Retrospective medical record review from Jan 1995 to Dec 2014. Data that were extracted from the medical records included signalment, body weight, underlying indication for leflunomide, dosage of leflunomide, treatment duration, concurrent medications, treatment response, and adverse events. Results Adverse events that could be related to leflunomide administration included diarrhea (3 of 92, 3.3%), lethargy (2 of 92, 2.2%), unexplained hemorrhage (3 of 92, 3.3%), thrombocytopenia (2 of 31, 6.5%), and increased liver enzyme activities (1 of 16, 6.3%). Significant dose differences between dogs with adverse events (n = 11; median, 2.9 mg/kg/d; range, 1.8–3.6 mg/kg/d) and dogs without adverse events (n = 81; median, 1.6 mg/kg/d; range, 0.8–4.3 mg/kg/d) were found (P < 0.001). Treatment response could be evaluated in 17 dogs. Of these 17 dogs, 12 dogs (70.5%) had an apparent positive response to the use of leflunomide. There was no significant difference (P = 0.22) in dosages between dogs that responded to leflunomide (n = 12; median, 1.9 mg/kg/d; range, 1.0–3.5 mg/kg/d) and those that did not respond (n = 5; median, 1.7 mg/kg/d; range, 1.0–2.0 mg/kg/d). Conclusions and Clinical Importance Results suggest that the starting dosage of leflunomide should be 2 mg/kg/d rather than the currently suggested dosage of 3–4 mg/kg/d.
Collapse
|
103
|
Ottensooser F, Leon N, Sato M. Individual Differences within the B Group Detected by Lectins. Vox Sang 2017. [DOI: 10.1159/000460801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
104
|
Sato T, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M, Aizawa Y. P4447The effect of sodium glucose cotransporter-2 inhibitors, dapagliflozin treatment on epicardial adipose tissue volume. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
105
|
Nagasaka T, Funada R, Umeyama A, Sato M, Takama N, Kurabayashi M. P870Long-term outcome of hemodialysis patients after deferral revascularization based on functional flow reverse. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
106
|
Hatayama Y, Aoki M, Kawaguchi H, Hirose K, Sato M, Akimoto H, Tanaka M, Fujioka I, Ichise K, Ono S, Takai Y. Clinical Results of Accelerated Hypofractionated Radiotherapy for Central-Type Small Lung Tumours. Curr Oncol 2017; 24:e285-e289. [DOI: 10.3747/co.24.3500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Purpose: We evaluated the efficacy and toxicity of accelerated hypofractionated radiotherapy (AHYPOF-RT) for central-type small lung tumours. Methods: Between November 2006 and January 2015, 40 patients with central-type small lung tumours underwent AHYPOF-RT delivered using 10 MV X-rays and a coplanar 3-field technique. The number of fractions ranged from 24 to 28, with a fraction size of 2.5–3 Gy. A total dose of 69–75 Gy to the isocentre of the planning target volume was administered to each patient. Cumulative survival and local control rates were calculated using the Kaplan–Meier method. Results: The 27 men and 13 women enrolled in the study had a median age of 79 years (range: 60−87 years). The tumour stage was T1a in 9 patients, T1b in 17 patients, and T2a in 14 patients, with a median size of 26.5 cm (range: 11–49 cm). The median follow-up period was 23 months. A complete response was achieved in 3 patients (7.5%), and a partial response, in 17 patients (42.5%). The overall 2-year and 3-year local control rates were 87.3% and 81.8% respectively; the 2-year and 3-year overall survival rates were 78.9% and 66.7% respectively. Grade 3 pneumonitis occurred in 3 patients; no other severe adverse events (≥grade 3) were observed in any patient. Conclusions: Accelerated hypofractionated radiotherapy using a fraction size of 2.5–3 Gy was highly safe and can be a more effective treatment option than conventional radiotherapy for patients with central-type small lung tumours.
Collapse
|
107
|
Higuchi M, Santos M, Ikegami R, Oiliveira L, Sato M, Bonsenor I, Lotufo P. P5570Worse outcome after acute myocardial infarction is related to archaeal microparticles and their exosomes. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
108
|
Kasahara S, Sakata Y, Nochioka K, Tsuji K, Abe R, Oikawa T, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. P3384Development of a simple risk score to predict mortality of patients with chronic heart failure with preserved ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
109
|
Sato M, Tateishi R, Yasunaga H, Matsui H, Fushimi K, Ikeda H, Yatomi Y, Koike K. Association between hospital volume and in-hospital mortality following radiofrequency ablation for hepatocellular carcinoma. BJS Open 2017; 1:50-54. [PMID: 29951606 PMCID: PMC5989986 DOI: 10.1002/bjs5.9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Accepted: 05/30/2017] [Indexed: 12/21/2022] Open
Abstract
Background Radiofrequency ablation (RFA) is a minimally invasive treatment for hepatocellular carcinoma (HCC). There is increasing evidence of an association between increasing hospital volume and lower postoperative mortality for many surgical procedures, but this is difficult to establish with minimally invasive treatments, where postoperative mortality is low. The aim of this study was to investigate the relationship between hospital volume and in-hospital mortality following RFA using a Japanese nationwide database. Methods Data from the Diagnostic Procedure Combination database were analysed from 1 July 2010 to 31 March 2012. Multivariable logistic regression was used to analyse the relationship between hospital volume and in-hospital mortality following RFA, with adjustment for patient background. Results Some 36 675 patients with HCC were identified in the database. The overall in-hospital mortality rate from RFA was 0·31 per cent. In-hospital mortality was significantly higher in low-volume than high-volume hospitals (odds ratio 2·57, 95 per cent c.i. 1·61 to 4·09; P < 0·001). Higher in-hospital mortality was significantly associated with older age and a higher Charlson Co-morbidity Index score. Conclusion RFA for HCC was associated with acceptably low mortality in Japan, but in-hospital mortality following RFA was affected by hospital procedural volume.
Collapse
|
110
|
Mizukami K, Sato M, Homma T, Natsui H, Kato M, Otsu K, Myojo T, Muto H, Fujita M, Takenaka T. P861Positioning an ECG electrode to the dorsal side can record higher amplitude of diaphragmatic compound motor action potentials (CMAP) during cryoballoon ablation. Europace 2017. [DOI: 10.1093/ehjci/eux151.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
111
|
Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M, Nomura Y. Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2017; 6:413-415. [PMID: 28568566 PMCID: PMC5529733 DOI: 10.1002/psp4.12203] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/20/2017] [Accepted: 04/21/2017] [Indexed: 12/25/2022]
Abstract
In Japan in October 2016, the Pharmaceuticals and Medical Devices Agency (PMDA) began to receive electronic data in new drug applications (NDAs). These electronic data are useful to conduct regulatory assessment of sponsors’ submissions and contribute to the PMDA's research. In this article, we summarize the number of submissions of quantitative modeling and simulation (M&S) documents in NDAs in Japan, and we describe our current thinking and activities about quantitative M&S in PMDA.
Collapse
|
112
|
Komori A, Morisaki T, Mutoh T, Sakakibara S, Takeiri Y, Kumazawa R, Kubo S, Ida K, Morita S, Narihara K, Shimozuma T, Tanaka K, Watanabe KY, Yamada H, Yoshinuma M, Akiyama T, Ashikawa N, Emoto M, Funaba H, Goto M, Ido T, Ikeda K, Inagaki S, Isobe M, Igami H, Itoh K, Kaneko O, Kawahata K, Kobuchi T, Masuzaki S, Matsuoka K, Minami T, Miyazawa J, Muto S, Nagayama Y, Nakamura Y, Nakanishi H, Narushima Y, Nishimura K, Nishiura M, Nishizawa A, Noda N, Ohdachi S, Oka Y, Osakabe M, Ohyabu N, Ozaki T, Peterson BJ, Sagara A, Saito K, Sakamoto R, Sato K, Sato M, Seki T, Shoji M, Sudo S, Tamura N, Toi K, Tokuzawa T, Tsumori K, Uda T, Watari T, Yamada I, Yokoyama M, Yoshimura Y, Motojima O, Beidler CD, Fujita T, Isayama A, Sakamoto Y, Takenaga H, Goncharov P, Ishii K, Sakamoto M, Murakami S, Notake T, Takeuchi N, Okajima S, Sasao M. Overview of Progress in LHD Experiments. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1229] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
113
|
Sugie T, Hatae T, Koide Y, Fujita T, Kusama Y, Nishitani T, Isayama A, Sato M, Shinohara K, Asakura N, Konoshima S, Kubo H, Takenaga H, Kawano Y, Kondoh T, Nagashima A, Fukuda T, Sunaoshi H, Naito O, Kitamura S, Tsukahara Y, Sakasai A, Sakamoto Y, Suzuki T, Tobita K, Nemoto M, Morioka A, Ishikawa M, Ishida S, Isei N, Oyama N, Neyatani Y, Itami K, Sakurai S, Tamai H, Tsuchiya K, Higashijima S, Nakano T, Nagaya S, Chiba S, Lee S, Shitomi M. Diagnostics System of JT-60U. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst02-a242] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
114
|
Kasai S, Kamiya K, Shinohara K, Kawashima H, Ogawa H, Uehara K, Miura Y, Okano F, Suzuki S, Hoshino K, Tsuzuki K, Sato M, Oasa K, Kusama Y, Yamauchi T, Nagashima Y, Ida K, Hidekuma S, Ido T, Hamada Y, Nishizawa A, Kawasumi Y, Uesugi Y, Okajima S, Kawahata K, Ejiri A, Amemiya H, Sadamoto Y. Plasma Diagnostics in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
115
|
Takeiri Y, Kaneko O, Tsumori K, Osakabe M, Ikeda K, Nagaoka K, Nakano H, Asano E, Kondo T, Sato M, Shibuya M, Komada S. High Performance of Neutral Beam Injectors for Extension of LHD Operational Regime. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a10834] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
116
|
Kamada Y, Fujita T, Ishida S, Kikuchi M, Ide S, Takizuka T, Shirai H, Koide Y, Fukuda T, Hosogane N, Tsuchiya K, Hatae T, Takenaga H, Sato M, Nakamura H, Naito O, Asakura N, Kubo H, Higashijima S, Miura Y, Yoshino R, Shimizu K, Ozeki T, Hirayama T, Mori M, Sakamoto Y, Kawano Y, Isayama A, Ushigusa K, Ikeda Y, Kimura H, Fujii T, Imai T, Nagami M, Takeji S, Oikawa T, Suzuki T, Nakano T, Oyama N, Sakurai S, Konoshima S, Sugie T, Tobita K, Kondoh T, Tamai H, Neyatani Y, Sakasai A, Kusama Y, Itami K, Shimada M, Ninomiya H, Urano H. Fusion Plasma Performance and Confinement Studies on JT-60 and JT-60U. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst02-a227] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
117
|
Tsumori K, Takeiri Y, Kaneko O, Osakabe M, Ando A, Ikeda K, Nagaoka K, Nakano H, Asano E, Shibuya M, Sato M, Kondo T, Komada M. Research and Development Activities on Negative Ion Sources. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a10835] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
118
|
Yamamoto M, Shibata T, Tsuzuki K, Sato M, Kimura H, Okano F, Kawashima H, Suzuki S, Shinohara K, Urata K. Engineering Design, Installation, and Conditioning of Ferritic Steel Plates/Wall for AMTEX in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
119
|
Tsuzuki K, Kimura H, Kusama Y, Sato M, Kawashima H, Kamiya K, Shinohara K, Ogawa H, Uehara K, Kurita G, Kasai S, Hoshino K, Isei N, Miura Y, Yamamoto M, Kikuchi K, Shibata T, Bakhtiari M, Hino T, Hirohata Y, Yamauchi Y, Yamaguchi K, Tsutsui H, Shimada R, Amemiya H, Nagashima Y, Ido T, Hamada Y. Characteristics of Plasma Operation with the Ferritic inside Wall and Its Compatibility with High-Performance Plasmas in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1095] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
120
|
Shimozuma T, Takahashi H, Kubo S, Yoshimura Y, Igami H, Takita Y, Kobayashi S, Ito S, Mizuno Y, Idei H, Notake T, Sato M, Ohkubo K, Watari T, Mutoh T, Minami R, Kariya T, Imai T. ECRH-Related Technologies for High-Power and Steady-State Operation in LHD. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst58-530] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
121
|
Shinohara K, Sato M, Kawashima H, Tsuzuki K, Suzuki S, Urata K, Isei N, Tani T, Kikuchi K, Shibata T, Kimura H, Miura Y, Kusama Y, Yamamoto M. Ripple Reduction with Ferritic Insert in JFT-2M. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst06-a1094] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
122
|
Nakano M, Oinuma M, Sato M, Asari J, Watanabe K, Kikuchi Y, Sakuma H. P12.18 A case of malignant meningioma with long-term recurrence free survival. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
123
|
Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. Abstract P4-21-03: A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
As for the HER2-positive breast cancer, there are many cases to be effective for neoadjuvant chemotherapy in comparison with other intrinsic subtypes. However, pCR is not provided by neoadjuvant chemotherapy in all cases. [Aim] This study evaluated the effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, relative to that of standard chemotherapy in patients with HER2-positive breast cancer. [patients and methods] Patients were randomly assigned to the control arm or the Ki-67 response-guided arm (Ki-67 arm). Primary tumor biopsies were obtained before treatment, and after three once-weekly doses of paclitaxel and trastuzumab to assess the interim Ki-67 index. In the control arm, paclitaxel and trastuzumab was continued for a total of 12 doses, regardless of the interim Ki-67 index. In the Ki-67 arm, subsequent treatment was based on the interim Ki-67 index. Early Ki-67 responders continued to received paclitaxel plus trastuzumab for a total of 12 doses, while early Ki-67 non-responders were switched to epirubicin plus cyclophosphamide every 3 weeks for three cycles with once-weekly trastuzumab for a total of 12 doses. The primary endpoint was the pathological complete response (pCR) rate. [Results] When 237 patients were enrolled, an interim analysis was conducted in 200 patients. There was almost linear correlation between the Ki-67 reduction rate at interim assessment and the pCR rate. The pCR rate in Ki-67 early non-responders in the Ki-67 arm (23.6%; 95% CI, 12.4 to 34.9) was inferior to that in the control arm (44.1%; 31.4 to 56.7; p=0.025). A strong correlation was not found between the Ki-67 reduction rate and the clinical response rate (Spearman's correlation coefficient 0.22).
pCR rate among Ki-67 early non-responders and responders TotalpCR nn%95%CIKi-67 early non responderControl arm59264431.4-56.7 Ki-67 response guided arm55132312.4-34.9Ki-67 early responderControl arm21104726.3-69.0 Ki-67 response guided arm2084018.5-61.5
Conclusions: The pCR rate in the Ki-67 arm was inferior to that in the control arm. A therapeutic strategy that switches chemotherapy, based on Ki-67 tumor expression after initial therapy, was not effective. The standard chemotherapy protocol remains as the recommended strategy for patients with HER2-positive breast cancer.
Citation Format: Takahashi M, Nishiyama Y, Hara F, Naito Y, Baba M, Sasaki M, Sato M, Watanabe K, Uemura Y, Yamaguchi T, Mukai H. A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-03.
Collapse
|
124
|
Nakagawa H, Kim SW, Hasegawa T, Hasegawa S, Ishigaki T, Uematsu K, Toda K, Takaba H, Sato M. Stabilization of novel high temperature phase yellow-emitting σ-type (Ba1−x−yEuxMgy)2P2O7 phosphors using a melt synthesis technique. Inorg Chem Front 2017. [DOI: 10.1039/c7qi00359e] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Novel high-temperature phase σ-type (Ba1−x−yEuxMgy)2P2O7 phosphors were synthesized for the first time by a melt synthesis technique using an arc-imaging furnace.
Collapse
|
125
|
Kim SW, Hasegawa T, Muto M, Toda A, Kaneko T, Sugimoto K, Uematsu K, Ishigaki T, Toda K, Sato M, Koide J, Toda M, Kudo Y. Improvement of luminescence properties of rubidium vanadate, RbVO3, phosphors by erbium doping in the crystal lattice. NEW J CHEM 2017. [DOI: 10.1039/c6nj03823a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The thermal quenching effect of RbVO3 phosphor was effectively improved by Er3+ doping into the lattice, as a result, the emission intensity of the phosphor was successfully enhanced.
Collapse
|